Literature DB >> 17639218

The Global Drug Facility: a unique, holistic and pioneering approach to drug procurement and management.

Robert Matiru1, Timothy Ryan.   

Abstract

In January 2006, the Stop TB Partnership launched the Global Plan to Stop TB 2006-2015, which describes the actions and resources needed to reduce tuberculosis (TB) incidence, prevalence and deaths. A fundamental aim of the Global Plan is to expand equitable access to affordable high-quality anti-tuberculous drugs and diagnostics. A principal tool developed by the Stop TB Partnership to achieve this is the Global Drug Facility (GDF). This paper demonstrates the GDFs unique, holistic and pioneering approach to drug procurement and management by analysing its key achievements. One of these has been to provide 9 million patient-treatments to 78 countries in its first 6 years of operation. The GDF recognized that the incentives provided by free or affordable anti-tuberculosis drugs are not sufficient to induce governments to improve their programmes standards and coverage, nor does the provision of free or affordable drugs guarantee that there is broad access to, and use of, drug treatment in cases where procurement systems are weak, regulatory hurdles exist or there are unreliable distribution and storage systems. Thus, the paper also illustrates how the GDF has contributed towards making sustained improvements in the capacity of countries worldwide to properly manage their anti-TB drugs. This paper also assesses some of the limitations, shortcomings and risks associated with the model. The paper concludes by examining the GDFs key plans and strategies for the future, and the challenges associated with implementation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17639218      PMCID: PMC2636664          DOI: 10.2471/blt.06.035402

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  1 in total

Review 1.  The Global TB Drug Facility: innovative global procurement.

Authors:  J Kumaresan; I Smith; V Arnold; P Evans
Journal:  Int J Tuberc Lung Dis       Date:  2004-01       Impact factor: 2.373

  1 in total
  7 in total

1.  Unemployment in TB patients - ten-year observation at regional center of pulmonology in Bydgoszcz, Poland.

Authors:  Grzegorz Przybylski; Anita Dabrowska; Marta Pilaczyńska-Cemel; Dorota Krawiecka
Journal:  Med Sci Monit       Date:  2014-11-02

Review 2.  Strengthening health systems by health sector reforms.

Authors:  Flavia Senkubuge; Moeketsi Modisenyane; Tewabech Bishaw
Journal:  Glob Health Action       Date:  2014-02-13       Impact factor: 2.640

Review 3.  Quality of drug-resistant tuberculosis care: Gaps and solutions.

Authors:  Zarir Udwadia; Jennifer Furin
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2019-04-24

4.  Quality assurance in anti-tuberculosis drug procurement by the Stop TB Partnership-Global Drug Facility: Procedures, costs, time requirements, and comparison of assay and dissolution results by manufacturers and by external analysis.

Authors:  Cathrin Hauk; Simon Schäfermann; Peter Martus; Nigorsulton Muzafarova; Magali Babaley; Brenda Waning; Lutz Heide
Journal:  PLoS One       Date:  2020-12-03       Impact factor: 3.240

5.  Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities.

Authors:  Emmanuela Gakidou; Stella Nordhagen; Ziad Obermeyer
Journal:  PLoS Med       Date:  2008-06-17       Impact factor: 11.069

6.  The growing problem of multidrug-resistant tuberculosis in North Korea.

Authors:  Kwonjune J Seung; Stephen W Linton
Journal:  PLoS Med       Date:  2013-07-30       Impact factor: 11.069

7.  The Global Drug Facility as an intervention in the market for tuberculosis drugs.

Authors:  Nimalan Arinaminpathy; Thierry Cordier-Lassalle; Kaspars Lunte; Christopher Dye
Journal:  Bull World Health Organ       Date:  2015-03-03       Impact factor: 9.408

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.